New drug to fight against cancer al breast. The combination of capivasertib plus fulvestrant has been approved by the European Union for the treatment of adult patients with locally advanced or metastatic breast cancer that is estrogen receptor-positive (ER-positive) and negative for Her2. The announcement was made by the manufacturing company. The approval was based on the results of the CAPItello-291 study, which showed that this combination reduced the risk of progression or death by 50% compared to fulvestrant alone in the population with altered biomarkers.
The results
These results were published in The New England Journal of Medicine. Alberto Zambelli, Associate Professor of Medical Oncology at Humanitas University of Milan, states: «In the majority of patients with hormone receptor-positive metastatic breast cancer, at least two lines of endocrine therapy should be preferred before moving on to chemotherapy. However, the endocrine-based treatment regimens currently used provide modest clinical benefit in many cases, and there is therefore an urgent need for new therapeutic options that guarantee longer-lasting disease control.”
«The main cause of death»
“Today’s approval is good news for approximately half of European patients with advanced ER-positive breast cancer who have tumors with these specific molecular alterations, and it is important that oncologists identify these patients who may benefit from this combination,” he added. “Breast cancer continues to be the leading cause of cancer death in Europe, and today’s news represents a significant step forward in our goal of providing an important new treatment option to patients who need innovative therapies,” said Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca.
© ALL RIGHTS RESERVED
Read the full article on
The morning
